Evidence map›Paper›PMID 27440441›Full record

ArticleRadiology2017

Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Etay Ziv, Joseph P Erinjeri, Hooman Yarmohammadi, F Edward Boas, Elena N Petre, Song Gao, Waleed Shady, Constantinos T Sofocleous, David R Jones, Charles M Rudin and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Radiogenomics in Interventional Oncology.Current oncology reports · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Etay ZivFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Joseph P ErinjeriFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Hooman YarmohammadiFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
F Edward BoasFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Elena N PetreFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Song GaoFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Waleed ShadyFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Constantinos T SofocleousFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
David R JonesFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Charles M RudinFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Stephen B SolomonFrom the Interventional Radiology Service, Department of Radiology (E.Z., J.P.E., H.Y., F.E.B., E.N.P., S.G., W.S., C.T.S., S.B.S.), Thoracic Service, Department of Surgery (D.R.J.), and Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (C.M.R.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard-118, New York, NY 10065; and the Interventional Therapy Department, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China (S.G.).
Memorial Sloan Kettering Cancer Center · USPeking University Cancer Hospital · CN

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Purpose To establish the relationship between KRAS mutation status and local recurrence after image-guided ablation of lung adenocarcinoma. Materials and Methods This study consisted of a HIPAA-compliant institutional review board-approved retrospective review of 56 primary lung adenocarcinomas in 54 patients (24 men, 30 women; median age, 72 years; range, 54-87 years) treated with percutaneous image-guided ablation and with available genetic mutational analysis. KRAS mutation status and additional clinical and technical variables-Eastern Cooperative Oncology Group (ECOG) status, smoking history, stage at diagnosis, status (new primary or not), history of radiation, history of surgery, prior systemic treatment, modality of ablation, size of nodule, ablation margin, and presence of ground-glass appearance-were recorded and evaluated in relation to time to local recurrence, which was calculated from the time of ablation to the first radiographic evidence of recurrence. Predictors of outcome were identified by using a proportional hazards model for both univariate and multivariate analysis, with death as a competing risk. Results Technical success was 100%. Of the 56 ablated tumors, 37 (66%) were wild type for KRAS and 19 (34%) were KRAS mutants. The 1-year and 3-year cumulative incidences of recurrence were 20% and 35% for wild-type KRAS compared with 40% and 63% for KRAS mutant tumors. KRAS mutation status was a significant predictor of local recurrence at both univariate (P = .05; subdistribution hazard ratio [sHR], 2.32) and multivariate (P = .006; sHR, 3.75) analysis. At multivariate analysis, size (P = .026; sHR, 2.54) and ECOG status (P = .012; sHR, 2.23) were also independent significant predictors, whereas minimum margin (P = .066) was not. Conclusion The results of this study show that there is a relationship between KRAS mutation status and local recurrence after image-guided ablation of lung adenocarcinoma. Specifically, KRAS mutation status of the ablated lesion is a significant predictor of time to local recurrence, independent of size and margin.

Indexed as

Ablation TechniquesAdenocarcinomaAdenocarcinoma of LungAgedAged, 80 and overCodonFemaleGenetic Predisposition to DiseaseGenotypeHumansLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalProto-Oncogene Proteins p21(ras)CodonKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID27440441
PMCPMC5207123
OpenAlexW2494151799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.